Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 12, 2025, titled "Aurobindo Pharma receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg and tentative approval for other strengths of Rivaroxaban Tablets USP".